Skip to main content

Biovie Inc.

BIVI
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001580149

In the last 90 days, Biovie Inc. insiders filed 4 open-market purchases and 0 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $2.88M in total; no superinvestor holds it.

Other share classesBIVIW

Key figures

Insider buysLast 90 days, $49.1K in total
4
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +2 vs. previous quarter
35
13F valueReported value at the end of Q2 2026
$2.88M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding BIVI, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding BIVI at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Biovie Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 28, 2026 (view filing)9:01 PM ETAug 28Same dayPalumbo Joseph MChief Medical OfficerPPurchase+4.84K$2.16+$10.5K+406.0%6.04K after
Aug 28, 2026 (view filing)9:01 PM ETAug 28Same dayChappell Amy SuzonDirectorPPurchase+727$2.16+$1.57KNew position727 after
Aug 28, 2026 (view filing)8:58 PM ETAug 28Same dayKim Joanne WendyChief Financial OfficerPPurchase+2.50K$2.18+$5.45K+265.7%3.44K after
Aug 28, 2026 (view filing)8:57 PM ETAug 271 dayDo Cuong VPresident & CEOPPurchase+15.2K$2.08+$31.6K+1,677.0%16.1K after
Aug 13, 2025 (view filing)Aug 76 daysLateDo Cuong VPresident & CEOPPurchase+5.00K––+100.2%9.99K after
Aug 13, 2025 (view filing)Aug 76 daysLateDo Cuong VPresident & CEOPPurchase+5.00K–––5.05K afterDerivative
Mar 6, 2024 (view filing)Mar 42 daysDo Cuong VPresident & CEOPPurchase+10.0K––+2.3%435.9K after
Mar 6, 2024 (view filing)Mar 42 daysDo Cuong VPresident & CEOPPurchase+5.00K–––5.00K afterDerivative
Dec 6, 2023 (view filing)Dec 15 daysLateGorlin SteveDirectorSSale−75.7K$1.69−$127.9K−62.0%46.4K after
Dec 1, 2023 (view filing)Nov 301 dayDo Cuong VPresident & CEOPPurchase+10.0K$1.78+$17.8K+17.0%68.8K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Biovie Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 35 holders
Institutions holding BIVI in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Morgan Stanley605,471$1.17M0.00%+530,250+704.9%Added
Diametric Capital, LP256,636$497.9K0.05%−113,364−30.6%Reduced
Renaissance Technologies LLC127,918$248.2K0.00%+60,000+88.3%Added
Citadel Advisors LLC95,952$186.1K0.00%+50,660+111.9%Added
Vanguard Capital Management LLC70,906$137.6K0.00%−13,161−15.7%Reduced
Geode Capital Management, LLC70,752$137.3K0.00%−13,451−16.0%Reduced
Philadelphia Trust Co50,010$97.0K0.01%−25,000−33.3%Reduced
Vanguard Fiduciary Trust Co37,557$72.9K0.00%00.0%Unchanged
Jane Street Group, LLC35,860$69.6K0.00%+13,069+57.3%Added
Prelude Capital Management, LLC32,583$63.2K0.00%−59,480−64.6%Reduced